使用依奇珠单抗的患者依从性显著高于司库奇尤单抗。如使用依奇珠单抗患者与司库奇尤单抗依从性比较所示,与使用司库奇尤单抗的患者相比,使用依奇珠单抗的患者对治疗有更高的依从性(治疗覆盖天数比例[PDC]≥80%:39.1% vs 31.6%; P=0.005)。在 24 个月的随访期间使用依奇珠单抗的治疗持续率高于司库奇尤单抗(37.2% vs 29.9%; P=0.005)使用依奇珠单抗的平均持续时间也显著长于司库奇尤单抗(427±270 天 vs 383±270 天; P=0.004)。3
1Damiani G, Conic RRZ, Pigatto PDM, et al. Young Dermatologists Italian Network. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019 May;32(3):e12886. doi: 10.1111/dth.12886.
2Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553-559. http://dx.doi.org/10.1111/jdv.15288
3Blauvelt A, Shi N, Somani N, et al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. J Am Acad Dermatol. 2022 Mar;86(3):581-589. doi: 10.1016/j.jaad.2021.06.878.